Prehab before cancer surgery: could exercise and nutrition cut complications?
NCT ID NCT07671625
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a program of physical therapy, nutritional planning, and psychological support before and after surgery can help patients with locally advanced esophageal, gastroesophageal junction, or stomach cancer recover better. Sixty participants will follow the program and be monitored for changes in fitness, sleep quality, fatigue, and quality of life. The goal is to reduce serious complications after surgery, which currently occur in up to 80% of patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- exercise, nutrition plan, and psychological support
- What this could lead to
- If successful, this program could help patients recover faster and with fewer complications after surgery for esophageal or stomach cancer.
- What could go wrong
- This is a small, early-stage study with only 60 participants, so results may not apply to everyone. The program requires significant effort and commitment from patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Consent to participate in the study * Age ≥ 18 years * Patients with locally advanced esophageal or gastric cancer indicated for comprehensive perioperative treatment * Resectable disease * ECOG performance status 0-2 * Ability to participate in a fitness program * Willingness to follow a nutritional plan and recommendations Exclusion Criteria: * Disseminated disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Masaryk Memorial Cancer Institute
RECRUITINGBrno, 65653, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors